AMST
Amesite Inc.·Technology
1.64
3.481%(+0.06)
Market OpenLast Updated: — ET
52W L: $0.7752W H: $4.78
AMST NEWS
gurufocus.com
May 19
Amesite Rips 250% On Its Largest AI Healthcare Deployment
Amesite (AMST) ripped 250% in premarket trading Tuesday after the AI software company secured a new enterprise customer representing an approximately 2,700-pati
feeds.benzinga.com
May 19
Amesite (AMST) Stock Is Trending Overnight — Here's Why It Moved Nearly 91% In After-Hours Session
Amesite shares jumped 90.82% after hours after announcing a major enterprise deployment and reporting strong year-over-year revenue growth.
globenewswire.com
May 18
Amesite's NurseMagic™ Wins 2,700-Census Home Care Enterprise Customer
Enterprise Deployment Validates AI-Native Infrastructure Strategy and Proves Scalable, Cost-Efficient Execution in Non-Acute Care Enterprise Deployment Validates AI-Native Infrastructure Strategy and Proves Scalable, Cost-Efficient Execution in Non-Acute Care
globenewswire.com
Apr 28
Amesite Announces Closing of Up To $7.8 Million Concurrent Registered Direct Offering and Private Placements Priced At-the-Market Under Nasdaq Rules
$2.6 million upfront with up to approximately $5.2 million of potential aggregate proceeds upon the exercise in full of warrants $2.6 million upfront with up to approximately $5.2 million of potential aggregate proceeds upon the exercise in full of warrants
globenewswire.com
Apr 28
Amesite Announces Insider-Led Private Placement Priced at a Premium to Market
DETROIT, April 28, 2026 (GLOBE NEWSWIRE) -- Amesite Inc. (Nasdaq: AMST), developer of the AI‑native NurseMagic™ platform and EMR for non‑acute care, today announced that it has entered into definitive agreements with certain of its officers and directors, including Dr. Ann Marie Sastry, Ph.D, its Chairman and CEO, and George Parmer, a member of its board of directors, for the purchase and sale of an aggregate of 418,118 shares of its common stock, Series A-1 warrants to purchase an aggregate up to 418,118 shares of the Company's common stock and Series A-2 warrants to purchase an aggregate up to 418,118 shares of the Company's common stock at a purchase price of $1.435 per share and accompanying warrants. The private placement follows the Company's recently announced concurrent registered direct offering and private placement, priced at-the-market under Nasdaq rules, which is expected to result in aggregate gross proceeds to the Company of approximately $2 million, before deducting placement agent fees and other offering expenses.
globenewswire.com
Apr 27
Amesite Announces Up To $6 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
DETROIT, April 27, 2026 (GLOBE NEWSWIRE) -- Amesite Inc. (Nasdaq: AMST), developer of the AI‑native NurseMagic™ platform and EMR for non‑acute care, today announced that it has entered into definitive agreements for the purchase and sale of 696,866 shares of its common stock, at a purchase price of $1.435 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, the Company has agreed to issue to the investor unregistered Series A-1 warrants to purchase up to 696,866 shares of common stock and unregistered Series A-2 warrants to purchase up to 696,866 shares of common stock.
